Posted On: 09/30/2014 8:50:37 PM
Post# of 273351
Actavis Inc (ACT) 241.28 $ACT
Ireland Exporters Look To Thursday's ECB Policy Vote
at Investor's Business Daily - 2 hrs 26 mins ago
As the eurozone awaits a key announcement from the European Central Bank, and as the dollar caps its powerful third-quarter advance vs. the euro, Ireland's economy this month reported its Q2 GDP surged 7.7% -- its best performance since 2007. The...
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast
PR Newswire - Tue Sep 30, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced that it intends to release third quarter 2014 financial results on Wednesday, November 5, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:00 a.m. Eastern Standard Time on Wednesday, November 5, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 8164798.
Facebook Among 5 IBD 50 Stocks Holding Near Highs
at Investor's Business Daily - Sat Sep 27, 7:02AM CDT
Facebook and Foot Locker are among five IBD 50 stocks that are holding at or near highs while other leaders come under pressure along with the general market. The IBD 50 list companies that are weathering the recent turmoil include some facing or...
Meet 5 Top Stocks With Rising Earnings Estimates
at Investor's Business Daily - Fri Sep 26, 7:02AM CDT
With earnings season set for kickoff, analysts are sizing up companies to adjust their stock forecasts. Today's Screen Of The Day is Leaders With Rising Estimates: stocks like Gilead Sciences (GILD) that are seeing analysts raise their earnings...
Actavis Confirms Generic Butrans® Patent Challenge
PR Newswire - Thu Sep 25, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Transdermal System, 5 mcg/hr, 10 mcg/hr and 20 mcg/hr. Actavis' ANDA product is a generic version of Purdue Pharma's Butrans®, which is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
Is It Time to Buy Dividend Stock Teva Pharmaceutical Industries Ltd?
George Budwell, The Motley Fool - Motley Fool - Thu Sep 25, 8:01AM CDT
Dividend stocks are a pivotal part of a balanced portfolio because they provide income and can help to lower the average purchase price of shares over time through dividend reinvestment plans. Picking the right dividend stocks that offer stable...
Should Pfizer Inc. Buy Actavis plc?
George Budwell, The Motley Fool - Motley Fool - Thu Sep 25, 7:27AM CDT
The patent cliff has radically transformed the healthcare landscape. Many, if not all, Big Pharmas simply aren't what they once were at the height of their commercial prowess. What has emerged from the wreckage is a handful of household names flush...
Facebook, Three Other Leaders In Striking Distance
at Investor's Business Daily - Wed Sep 24, 10:36PM CDT
Even though the market uptrend is under pressure again, many leading stocks remain well extended and out of buying range. But a few have pulled back or been unable to make much headway following breakouts, leaving them near buy points. Facebook (FB)...
Allergan and Salix Pharmaceuticals Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 3:45PM CDT
Allergan Inc. (AGN) and Salix Pharmaceuticals Ltd. (SLXP) were up after a report from The Wall Street Journal indicated that the former has renewed its attempts to acquire the latter.
Valeant Ends Prince Charming Act; Allergan Hopes Rise
at Investor's Business Daily - Wed Sep 24, 3:23PM CDT
Valeant Pharmaceuticals (VRX) shares popped on upbeat guidance and as the addition of Actavis (ACT) to the Allergan-Valeant-Salix triangle lifted Valeant's chances for an Allergan takeover. Valeant said it expects to beat third-quarter analyst views...
P&G Exits Pet Care; To Vend Europe Unit to Spectrum Brands - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 1:00PM CDT
The Procter & Gamble Company (PG) announced plans to sell the remainder of the its pet care business in Europe to consumer products company, Spectrum Brands Holdings, Inc. (SPB).
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver
PR Newswire - Wed Sep 24, 9:37AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TKMR, HLF, AA, ACT and TWTR.
Pfizer
at Investor's Business Daily - Tue Sep 23, 5:45PM CDT
Pfizer (PFE) is exploring a bid for Actavis (ACT) and has approached officials at the generic-drug firm, but formal talks haven't started, according to Bloomberg sources. Pfizer shares fell 0.4% to 30.05. Actavis rose 2.2% to 240.85.
Stocks Finish Lower Among Takeover Rumors
at Investor's Business Daily - Tue Sep 23, 5:06PM CDT
Stocks finished the day down moderately, with the Nasdaq and the S&P 500 lower for the third straight day. Volume was running lighter than the previous day, according to preliminary figures. The Nasdaq was down 0.4%; the S&P 500 fell 0.6% and the Dow...
Why Actavis (ACT) Stock Is Higher Today
at The Street - Tue Sep 23, 1:36PM CDT
Pfizer( PFE) reportedly approached the company to express its interest in an acquisition, as Pfizer continues to explore ways to cut its tax rate and gain a new product pipeline.
Actavis (ACT) Marked As A Barbarian At The Gate
at The Street - Tue Sep 23, 1:25PM CDT
Trade-Ideas LLC identified Actavis (ACT) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Video: Allergan-Ackman War Reignites On Salix Rumors
at Investor's Business Daily - Tue Sep 23, 10:47AM CDT
Salix Pharmaceuticals jumped 6% to a new high above 169 on the stock market today on news that fellow specialty drugmaker Allergan is probably about to buy it. However, one of Allergan's largest shareholders threatened to sue if the two companies...
Indexes Pare Losses As Salix Soars On Buyout Talk
at Investor's Business Daily - Tue Sep 23, 9:56AM CDT
Major averages pared some of their early losses and were mixed in late-morning trading as investors weighed mixed economic reports from China, Europe and the U.S., as well as U.S. airstrikes in Syria. The Nasdaq was up 0.1%, while the S&P 500 was...
Why Actavis (ACT) Stock Is Down Today
at The Street - Mon Sep 22, 2:22PM CDT
Shares of Actavis (ACT) are lower after the company was downgraded to 'equal-weight' from 'overweight' by Barclays.
Ireland Exporters Look To Thursday's ECB Policy Vote
at Investor's Business Daily - 2 hrs 26 mins ago
As the eurozone awaits a key announcement from the European Central Bank, and as the dollar caps its powerful third-quarter advance vs. the euro, Ireland's economy this month reported its Q2 GDP surged 7.7% -- its best performance since 2007. The...
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast
PR Newswire - Tue Sep 30, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced that it intends to release third quarter 2014 financial results on Wednesday, November 5, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:00 a.m. Eastern Standard Time on Wednesday, November 5, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 8164798.
Facebook Among 5 IBD 50 Stocks Holding Near Highs
at Investor's Business Daily - Sat Sep 27, 7:02AM CDT
Facebook and Foot Locker are among five IBD 50 stocks that are holding at or near highs while other leaders come under pressure along with the general market. The IBD 50 list companies that are weathering the recent turmoil include some facing or...
Meet 5 Top Stocks With Rising Earnings Estimates
at Investor's Business Daily - Fri Sep 26, 7:02AM CDT
With earnings season set for kickoff, analysts are sizing up companies to adjust their stock forecasts. Today's Screen Of The Day is Leaders With Rising Estimates: stocks like Gilead Sciences (GILD) that are seeing analysts raise their earnings...
Actavis Confirms Generic Butrans® Patent Challenge
PR Newswire - Thu Sep 25, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Transdermal System, 5 mcg/hr, 10 mcg/hr and 20 mcg/hr. Actavis' ANDA product is a generic version of Purdue Pharma's Butrans®, which is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
Is It Time to Buy Dividend Stock Teva Pharmaceutical Industries Ltd?
George Budwell, The Motley Fool - Motley Fool - Thu Sep 25, 8:01AM CDT
Dividend stocks are a pivotal part of a balanced portfolio because they provide income and can help to lower the average purchase price of shares over time through dividend reinvestment plans. Picking the right dividend stocks that offer stable...
Should Pfizer Inc. Buy Actavis plc?
George Budwell, The Motley Fool - Motley Fool - Thu Sep 25, 7:27AM CDT
The patent cliff has radically transformed the healthcare landscape. Many, if not all, Big Pharmas simply aren't what they once were at the height of their commercial prowess. What has emerged from the wreckage is a handful of household names flush...
Facebook, Three Other Leaders In Striking Distance
at Investor's Business Daily - Wed Sep 24, 10:36PM CDT
Even though the market uptrend is under pressure again, many leading stocks remain well extended and out of buying range. But a few have pulled back or been unable to make much headway following breakouts, leaving them near buy points. Facebook (FB)...
Allergan and Salix Pharmaceuticals Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 3:45PM CDT
Allergan Inc. (AGN) and Salix Pharmaceuticals Ltd. (SLXP) were up after a report from The Wall Street Journal indicated that the former has renewed its attempts to acquire the latter.
Valeant Ends Prince Charming Act; Allergan Hopes Rise
at Investor's Business Daily - Wed Sep 24, 3:23PM CDT
Valeant Pharmaceuticals (VRX) shares popped on upbeat guidance and as the addition of Actavis (ACT) to the Allergan-Valeant-Salix triangle lifted Valeant's chances for an Allergan takeover. Valeant said it expects to beat third-quarter analyst views...
P&G Exits Pet Care; To Vend Europe Unit to Spectrum Brands - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 1:00PM CDT
The Procter & Gamble Company (PG) announced plans to sell the remainder of the its pet care business in Europe to consumer products company, Spectrum Brands Holdings, Inc. (SPB).
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver
PR Newswire - Wed Sep 24, 9:37AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TKMR, HLF, AA, ACT and TWTR.
Pfizer
at Investor's Business Daily - Tue Sep 23, 5:45PM CDT
Pfizer (PFE) is exploring a bid for Actavis (ACT) and has approached officials at the generic-drug firm, but formal talks haven't started, according to Bloomberg sources. Pfizer shares fell 0.4% to 30.05. Actavis rose 2.2% to 240.85.
Stocks Finish Lower Among Takeover Rumors
at Investor's Business Daily - Tue Sep 23, 5:06PM CDT
Stocks finished the day down moderately, with the Nasdaq and the S&P 500 lower for the third straight day. Volume was running lighter than the previous day, according to preliminary figures. The Nasdaq was down 0.4%; the S&P 500 fell 0.6% and the Dow...
Why Actavis (ACT) Stock Is Higher Today
at The Street - Tue Sep 23, 1:36PM CDT
Pfizer( PFE) reportedly approached the company to express its interest in an acquisition, as Pfizer continues to explore ways to cut its tax rate and gain a new product pipeline.
Actavis (ACT) Marked As A Barbarian At The Gate
at The Street - Tue Sep 23, 1:25PM CDT
Trade-Ideas LLC identified Actavis (ACT) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Video: Allergan-Ackman War Reignites On Salix Rumors
at Investor's Business Daily - Tue Sep 23, 10:47AM CDT
Salix Pharmaceuticals jumped 6% to a new high above 169 on the stock market today on news that fellow specialty drugmaker Allergan is probably about to buy it. However, one of Allergan's largest shareholders threatened to sue if the two companies...
Indexes Pare Losses As Salix Soars On Buyout Talk
at Investor's Business Daily - Tue Sep 23, 9:56AM CDT
Major averages pared some of their early losses and were mixed in late-morning trading as investors weighed mixed economic reports from China, Europe and the U.S., as well as U.S. airstrikes in Syria. The Nasdaq was up 0.1%, while the S&P 500 was...
Why Actavis (ACT) Stock Is Down Today
at The Street - Mon Sep 22, 2:22PM CDT
Shares of Actavis (ACT) are lower after the company was downgraded to 'equal-weight' from 'overweight' by Barclays.
(0)
(0)
